More than 8 million Americans experience the physical, psychological, and emotional toll of psoriasis, but people of color experience additional challenges due to limited medical research, education, and underrepresentation in clinical studies. To help address these critical gaps, the Janssen Pharmaceutical Companies of Johnson & Johnson announced the initiation of VISIBLE. VISIBLE is a first-of-its-kind, large-scale prospective clinical study dedicated to generating key disease insights among Black, Hispanic, Asian, Indigenous, and other people of color. This study reinforces Janssen’s commitments to inclusive clinical research and addressing health inequities.
ReAd full press release
Categories:
Blog, Industry
Tags: janssen, visible, people of color, inclusive clinical research